Nucleix
27 Habarzel Street
Tel Aviv
69710
Tel: 972-3-7684935
Fax: 972-3-7684945
Website: http://www.nucleix.com/
Email: info@nucleix.com
30 articles about Nucleix
-
Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes
4/4/2024
Nucleix Demonstrates Potential of its PCR EpiCheck ® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes.
-
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands
11/6/2023
Nucleix Receives Reimbursement for Bladder EpiCheck ® in the Netherlands.
-
Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer
10/11/2023
Nucleix today announced recent updates in its lung cancer detection program for early-stage disease.
-
Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting
10/2/2023
Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck ® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting.
-
Nucleix Appoints Michael G. Vicari as Chief Commercial Officer
6/6/2023
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.
-
Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence
5/4/2023
Nucleix has received 510 clearance from the U.S. Food and Drug Administration to market Bladder EpiCheck® for use as a non-invasive method for surveillance of tumor recurrence in patients previously diagnosed with non-muscle invasive bladder cancer, in conjunction with cystoscopy.
-
Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting
4/13/2023
Nucleix will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19.
-
Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory
10/19/2022
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that their San Diego-based clinical laboratory received accreditation by the College of American Pathologists (CAP).
-
Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer
6/22/2022
Nucleix Expands EU Label Indication of Bladder EpiCheck ® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer.
-
Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program
1/5/2022
Nucleix announced recent advances in its EpiCheck ® Next Generation Sequencing (NGS) platform and lung cancer detection program for early stage disease.
-
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
7/11/2021
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology Virtual Congress.
-
Nucleix Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
6/3/2021
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center
-
Nucleix’s Lung EpiCheck® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal
10/29/2020
Nucleix’s Lung EpiCheck ® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal Cost-effective blood test, combined with patient clinical factors, significantly improves AUC to 94%
-
Independent Review, Published in International Journal of Molecular Sciences, Supports Accuracy and Performance of Nucleix’s Bladder EpiCheck® Urine Test in Detecting Non-Muscle Invasive Bladder Cancer Recurrence
9/24/2020
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a published independent review of Bladder EpiCheck studies which showed high diagnostic accuracy and high performance
-
Nucleix Presents Two Bladder EpiCheck® Studies at EAU20 Virtual Congress, Including Interim Data in Patients with Upper Tract Urothelial Cancer
7/17/2020
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced two presentations featuring its Bladder EpiCheck® technology at the 35 th Annual European Association of Urology (EAU) Virtual Congress. The first presentation, titled “Feasibility of the EpiCheck test in upper tract tumor: interim analysis of a prospective trial,” evaluated 47 patie
-
Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology
6/29/2020
Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder cancer population undergoing instillations Study conducted at Agostino Gemelli University Hospital in Rome, Italy, shows it would be safe and effective to use Bladder EpiCheck to avoid unnecessary cystoscopies in high-risk patients SAN DIEGO & REHOVOT, Israel--( BUSINESS WIRE )-- Nucle
-
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
-
Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early Cancers
5/26/2020
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020. The six-marker assay serves as an initial component of Nucleix’s screening
-
BioSpace Movers & Shakers, May 15
5/15/2020
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers. -
Nucleix Strengthens Leadership and Expands Footprint for U.S. Growth of Liquid Biopsy Development
5/11/2020
May 11, 2020 13:00 UTC Company appoints new CEO, CFO, General Manager and board member, opens San Diego office SAN DIEGO & REHOVOT, Israel--( BUSINESS WIRE )-- Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the expansion of its operations into the United States and the appointment of new executive and board leadership to support future growth. The company appointed Chris Hibberd as chief executi